120 related articles for article (PubMed ID: 27206322)
1. Acquired hemophilia A and fulminant diabetes mellitus possibly caused by adalimumab in a patient with psoriatic arthritis.
Yamaguchi T; Itoh M; Umezawa Y; Asahina A; Hanabusa H; Nakagawa H
J Dermatol; 2017 Mar; 44(3):e3-e4. PubMed ID: 27206322
[No Abstract] [Full Text] [Related]
2. Ocular adnexal B-cell hyperplasia associated with adalimumab.
Ao J; Curragh DS; Otto S; Selva D
Clin Exp Ophthalmol; 2019 Nov; 47(8):1096-1097. PubMed ID: 31271492
[No Abstract] [Full Text] [Related]
3. SB5 adalimumab biosimilar in the treatment of psoriasis and psoriatic arthritis.
Di Cesare A; Tronconi G; Fastame TM; Rosi E; Pescitelli L; Ricceri F; Prignano F
Dermatol Ther; 2020 May; 33(3):e13435. PubMed ID: 32306527
[No Abstract] [Full Text] [Related]
4. Severe subcutaneous hematoma in a patient with psoriatic arthritis: Changes of platelet count in psoriatic patients with biologic agents.
Maya Y; Fujita Y; Nakayama C; Kitamura S; Hata H; Arita K; Shimizu H
J Dermatol; 2017 Dec; 44(12):1385-1388. PubMed ID: 28733978
[TBL] [Abstract][Full Text] [Related]
5. Brain abscess in a patient with psoriatic arthritis treated with adalimumab: A case report.
Lo YP; Desale S; Wu PY
Medicine (Baltimore); 2020 Mar; 99(10):e18954. PubMed ID: 32150046
[TBL] [Abstract][Full Text] [Related]
6. Fatal acquired hemophilia A in a patient with rheumatoid arthritis treated with adalimumab.
Arthanari S; Ahmad H; Nisar M
J Clin Rheumatol; 2012 Jan; 18(1):50-1. PubMed ID: 22157274
[No Abstract] [Full Text] [Related]
7. Acquired hemophilia, rheumatoid arthritis, and TNFα antagonists: Comment on the article "Acquired hemophilia possibly induced by etanercept in a patient with rheumatoid arthritis" by Banse et al., Joint Bone Spine 2015;82:200-2.
Brinster A; Bertrand MA; Guillot X; Sondag M; Wendling D
Joint Bone Spine; 2015 Oct; 82(5):384-5. PubMed ID: 26027776
[No Abstract] [Full Text] [Related]
8. Arthritis possibly induced and exacerbated by a tumour necrosis factor antagonist in a patient with psoriasis vulgaris.
Takahashi T; Asano Y; Shibata S; Nakamura K; Nakao M; Shida R; Mitsui A; Araki M; Watanabe R; Fujita H; Tada Y; Sato S
Br J Dermatol; 2015; 172(5):1458-60. PubMed ID: 25565011
[No Abstract] [Full Text] [Related]
9. Adalimumab-Induced Epstein-Barr Virus-Related Lymphoproliferative Disorder on FDG PET/CT.
Ward J; Noy A; Ulaner G; Riedl C
Clin Nucl Med; 2018 May; 43(5):344-345. PubMed ID: 29538028
[TBL] [Abstract][Full Text] [Related]
10. Impact of adalimumab on symptoms of psoriatic arthritis in patients with moderate to severe psoriasis: a pooled analysis of randomized clinical trials.
Mease PJ; Signorovitch J; Yu AP; Wu EQ; Gupta SR; Bao Y; Mulani PM
Dermatology; 2010; 220(1):1-7. PubMed ID: 19940437
[TBL] [Abstract][Full Text] [Related]
11. Injection site reactions of adalimumab spreading on the trunk in a psoriatic arthritis patient.
Kato Y; Kawakami Y; Yamamoto T
J Dermatol; 2013 Nov; 40(11):931-2. PubMed ID: 24112030
[No Abstract] [Full Text] [Related]
12. Case Report: Effective management of adalimumab-induced acquired hemophilia A with the CyDRI protocol.
Ceglédi A; Bátai Á; Dolgos J; Fekete M; Gopcsa L; Király V; Lakatos G; Nagy G; Szemlaky Z; Várkonyi A; Vilimi B; Mikala G; Bodó I
Pathol Oncol Res; 2024; 30():1611720. PubMed ID: 38846411
[TBL] [Abstract][Full Text] [Related]
13. Adalimumab: in psoriatic arthritis.
Simpson D; Scott LJ
Drugs; 2006; 66(11):1487-96; discussion 1497-9. PubMed ID: 16906782
[TBL] [Abstract][Full Text] [Related]
14. Hypertriglyceridaemia during treatment with adalimumab in psoriatic arthritis.
Stinco G; Piccirillo F; Patrone P
Br J Dermatol; 2007 Dec; 157(6):1273-4. PubMed ID: 17916219
[No Abstract] [Full Text] [Related]
15. Real-life 10-year retention rate of first-line anti-TNF drugs for inflammatory arthritides in adult- and juvenile-onset populations: similarities and differences.
Favalli EG; Pontikaki I; Becciolini A; Biggioggero M; Ughi N; Romano M; Crotti C; Gattinara M; Gerloni V; Marchesoni A; Meroni PL
Clin Rheumatol; 2017 Aug; 36(8):1747-1755. PubMed ID: 28597133
[TBL] [Abstract][Full Text] [Related]
16. Severe glandular tularemia in a patient treated with anti-tumour necrosis factor for psoriatic arthritis.
Calin R; Caumes E; Reibel F; Ali Mohamed A; Brossier F; Foltz V; Boussouar S; Fautrel B; Maurin M; Katlama C; Pourcher V
Int J Infect Dis; 2017 Jul; 60():1-3. PubMed ID: 28450199
[TBL] [Abstract][Full Text] [Related]
17. Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial.
Gladman DD; Mease PJ; Ritchlin CT; Choy EH; Sharp JT; Ory PA; Perdok RJ; Sasso EH
Arthritis Rheum; 2007 Feb; 56(2):476-88. PubMed ID: 17265483
[TBL] [Abstract][Full Text] [Related]
18. Exacerbation of psoriatic skin lesions in a patient with psoriatic arthritis receiving adalimumab.
Borrás-Blasco J; Gracia-Perez A; Nuñez-Cornejo C; Rosique-Robles JD; Mateu-Puchades A; Casterá MD; Rubio-Fabra M
J Clin Pharm Ther; 2008 Jun; 33(3):321-5. PubMed ID: 18452420
[TBL] [Abstract][Full Text] [Related]
19. Onset of palmoplantar pustular psoriasis while on adalimumab for psoriatic arthritis: a 'class effect' of TNF-alpha antagonists or simply an anti-psoriatic treatment adverse reaction?
Rallis E; Korfitis C; Stavropoulou E; Papaconstantis M
J Dermatolog Treat; 2010 Jan; 21(1):3-5. PubMed ID: 19701844
[TBL] [Abstract][Full Text] [Related]
20. Amyotrophic lateral sclerosis developing during adalimumab therapy for psoriatic arthritis.
Bougea A; Anagnostou E; Stamboulis E; Kararizou E
Rev Neurol (Paris); 2014 Mar; 170(3):228-9. PubMed ID: 24656415
[No Abstract] [Full Text] [Related]
[Next] [New Search]
